The aim of this study was to determine the concentration of galectin-3, PINP and PIIINP in patients with metabolic syndrome (MS) and atrial fibrillation (AF) with an assessment of the relationship with severity of left atrium fibrosis. A total of 480 subjects were included in the case-control study: MS patients (n = 337), 176 of whom had AF, 72 patients with AF without MS and 71 healthy subjects. Galectin-3, PINP and PIIINP blood concentrations and metabolic parameters were compared with the severity of left atrium fibrosis, measured by CARTO3. Galectin-3 in AF and MS patients is higher than in MS without AF and in healthy subjects (10.3 (4.8–15.4), 5.1 (4.3–8.8), 3.2 (2.4–4.2) ng/mL, p < 0.0001). Galectin-3 serum concentration in AF patients with MS is higher than in patients without MS: 10.3 (4.8–15.4), 6.8 (5.2–8.1) ng/mL, p = 0.0001. PINP and PIIINP concentration were higher in patients with AF and MS than in MS without AF: 3499.1 (2299.2–4567.3), 2130.9 (1425.3–2861.8) pg/mL, p < 0.0001, 94.9 (64.8–123.5), 57.6 (40.5–86.9) ng/mL, p < 0.0001. Galectin-3 correlates with PINP (r = 0.496, p < 0.001) and PIIINP concentration (r = 0.451, p < 0.0001). The correlation between galectin-3, PINP and the severity of left atrium fibrosis was found (r = 0.410, p < 0.001; r = 0.623, p < 0.001). Galectin-3 higher than 12.6 ng/mL increased the risk of AF more than five-fold. High galectin-3, PINP and PIIINP concentrations were associated with heart remodeling in MS patients and increased the risk of AF.

No abstract

No abstract

No abstract

Saint Petersburg, RussiaPurpose: Galectin 3 (Gal 3) -biomarker of fibrosis is increased in serum patients with atrial fibrillation (AF) and metabolic syndrome (MetS). We propose that Gal 3 can impact on progression of the arrhythmia. Objective of the study is to evaluate the role of Gal 3 in predicting the effect of antiarrhythmic drug therapy in patients with AF and MetS. Method: 180 patients with MetS (IDF, 2005) and paroxysmal (n ¼ 100) or persistent (n ¼ 80) AF were examined. Groups did not differ significantly by gender, age, eGFR ( p . 0,05), volumes left and right atrium. The examination includes: medical history, anthropometry, echocardiography, serum Gal 3 (ELISA). Patients were taking antiarrhythmic drugs: amiodarone (32%), beta-blockers (42%), sotalol (12%), propafenone (14%) during 16,7 + 6,9 months. After that we analyzed the clinical data and the effectiveness of antiarrhythmic drug therapy, which is considered effective if there were no reported paroxysms of AF during follow-up. Results: Serum Gal 3 in patients with persistent AF was higher compared to patients with paroxysmal AF (1,02 [0,52;3,14] and 0,54 [0,41;1,31] ng/ml, r ¼ 0,03). In patients with 1-2 paroxysms in month serum Gal 3 was higher than in patients with 1-2 paroxysms in year (1,31 [0,92;4,21] and 0,53 [0,41;0,72] ng/ml, r , 0,001). Serum Gal 3 in patients with recurrent paroxysms of AF and without the effect of antiarrhythmic therapy was higher than in patients without recurrent paroxysms of AF irrespective of antiarrhythmic drug (1,31 [0,75,2,49] and 0,50 [0,41;0,72] ng / ml, p , 0.001). The multivariate regression analysis demonstrated that Gal 3 is an independent predictor of non-effective antiarrhythmic drug therapy of AF (OR ¼ 2,38, 95% CI 1,12-5,04, p ¼ 0.024). In patients with AF and MetS who had serum Gal 3 above 0,77 ng/ml (cut-off point on ROC-curve) the risk of non-effective antiarrhythmic therapy was in 3,6 fold higher during follow-up the study (RR ¼ 3,6, 95% CI 1,6-7,9, p ¼ 0,002). Conclusions:The level of serum galectin 3 in patients with persistent atrial fibrillation is higher than in patients with paroxysmal. Patients with higher level of galectin 3 have a higher risk of non-effective antiarrhythmic drug therapy, that may be an additional indication for surgical treatment. Conflict of interest: none THE IMPACT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION FOR THE VERY LATE RECURRENCE AFTER THE MULTIPLE ATRIAL FIBRILLATION ABLATIONSNaoaki Onishi, Kazuaki Kaitani, Sari Imamura, Chisato Izumi, and Yoshihisa Nakagawa Tenri, Nara, Japan Purpose: Procedural failure can contribute to early and late recurrences after catheter ablation (CA) session for atrial fibrillation (AF), but there could be different mechanisms for very late recurrence (VLR; initial recurrence .12 months after multiple CA sessions). However, predictors of VLR remain unidentified. This study investigated whether the left ventricular diastolic dysfunction (LVDD) is associated with VLR after multiple CAs for AF. Method: From December 2011 to April 201...

No abstract

No abstract

No abstract